about
Trial WatchMetronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinomaThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseImmunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategiesTrial Watch: Adoptive cell transfer for oncological indicationsPrognostic and Predictive Value of DAMPs and DAMP-Associated Processes in CancerEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityCD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growthChloroquine and hydroxychloroquine for cancer therapyGenetically modified T cells for the treatment of malignant diseaseSystems biology of cisplatin resistance: past, present and futureTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsTrial Watch: Immunogenic cell death inducers for anticancer chemotherapyTrial watch: IDO inhibitors in cancer therapyTrial Watch:: Oncolytic viruses for cancer therapyMetronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistanceTrial watch: Dendritic cell-based anticancer therapySerial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironmentUnderstanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapyTrial Watch-Oncolytic viruses and cancer therapyTrial Watch: Proteasomal inhibitors for anticancer therapyA2aR antagonists: Next generation checkpoint blockade for cancer immunotherapyEpirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell ActivityMolecular mechanisms of ATP secretion during immunogenic cell deathModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesTumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactionsCancer Immunoprevention and Public Health.Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity SetEnhanced cancer stem cell properties of a mitotically quiescent subpopulation of p75NTR-positive cells in esophageal squamous cell carcinoma.Trial Watch: Toll-like receptor agonists in oncological indications.Trial watch: Immunostimulatory cytokines in cancer therapy.Cancer targeted therapeutics: From molecules to drug delivery vehicles.Cancer immunotherapy in clinical practice -- the past, present, and future.Immunological thought in the mainstream of cancer research: Past divorce, recent remarriage and elective affinities of the future.Novel insights into the mechanism of action of lenalidomide.
P2860
Q24618653-70647E4D-B7DC-4310-9AB9-6C54E15AF7C7Q26753070-E21D1697-C3CF-48E2-9EA5-4EEE02E62A74Q26766066-104EC528-B4F8-4CD9-8B26-FB0DE89550CCQ26776184-1A7ED97F-B8CE-4CE9-A585-089EBE91F2F7Q26785545-3170226C-0E37-4AE5-B8BA-9D27B4CB63A8Q26795466-50E29CC4-CB8A-4848-BA69-7563656E16CCQ26796313-AEE33AFA-580A-49FE-96B9-9A08BC78A94FQ26823709-CE3E0132-314C-4FC3-88E0-6942916057AEQ26827797-BAE55D02-AD0F-474F-8ADA-92A22A0DBD20Q26860657-FB517C07-F403-4EEE-9738-07A8569F6B04Q26863585-38B9BBEF-36A8-40EF-B419-30BC7AFE7A26Q26993238-13F934DE-AB7E-4582-B4B2-901B256C3F56Q26996518-D9B0A319-04BA-4BC0-A5E5-1E50C3BD914DQ27004011-54C1D02A-8E17-43B2-A3A1-6851CFA3AEC3Q27006866-852BCF36-A63B-4DF1-ABC8-AE1183A4B16BQ27021951-6CEDF6EE-E9AB-44D1-B4B7-34CA9E31BFB4Q27023579-3257AA76-7086-4BC5-A485-46E9BEFE05A3Q27024047-FF6C2032-8AD4-4FE6-AEFC-219B66A819E0Q27335748-6E610FFF-C312-4510-AAC4-645E7B8234DEQ27691330-E6B6CCA2-9361-4C03-9EC8-601F3D68433CQ28067939-0A7B089F-79A0-4D8C-95ED-F91FC25C1768Q28072347-979F27E3-0F90-4A6F-80C2-E5BD1AD4CE17Q28082910-56DD2A19-278B-4E7D-84C9-74151AC84DA4Q28087576-2DC8F3BA-A0DE-41C5-B387-5EDE7E38AD04Q28550203-BA036742-CC6D-44A3-8C90-7E4B3BF191E9Q30408773-2003C490-F48E-413E-A4AA-C0ED968018ACQ30570945-95CC0413-B0EA-47C4-A50F-CB0A95200BAAQ30916013-1D86E03F-3097-48DB-AE01-7CA4145BAAB6Q33627023-7CDA752A-AD8A-45FA-915C-C55F5F7BEE13Q33646584-7FF85A03-D43D-461D-98DC-D999A28A8B10Q33679505-1E8A70BB-FD9C-45AA-BDB8-F18163ABDAA3Q33769821-1CFE199B-4A5C-4670-B7CD-5F0817DC00F1Q33776379-0B1B6AA1-2EE9-4A7A-B392-AE2D7BDDD206Q33788010-AEFAD756-56DA-4A4D-B1A9-D639549BAC8AQ33878578-61C453EE-6A8B-43D3-A2A7-BDA21F6C1317Q33880165-51F25365-3BC3-421F-9AB8-0834B9719DA0Q33887986-07845734-7C85-4B6F-8523-AFC2D5D6F3E7Q34309399-783480B0-E4B8-410F-AEF7-A1A49DC44726Q34312571-2907F7EE-A150-49F9-91D2-A4273C966BEEQ34373253-E5D0CE61-5229-4138-866C-86D27989EFD9
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The secret ally: immunostimulation by anticancer drugs.
@en
The secret ally: immunostimulation by anticancer drugs.
@nl
type
label
The secret ally: immunostimulation by anticancer drugs.
@en
The secret ally: immunostimulation by anticancer drugs.
@nl
prefLabel
The secret ally: immunostimulation by anticancer drugs.
@en
The secret ally: immunostimulation by anticancer drugs.
@nl
P50
P356
P1476
The secret ally: immunostimulation by anticancer drugs.
@en
P2888
P304
P356
10.1038/NRD3626
P577
2012-02-03T00:00:00Z
P5875
P6179
1014015173